Effect of extending the duration of carboplatin infusion in decreasing of hypersensitivity reaction in retreatment gynecologic cancer pateints

The Incidence of Hypersensitivity Reaction of Carboplatin Retreatment in Gynecologic Cancer Patients between 1 and 2 hours Infusion-The Randomized Study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20151123001

Enrollment

126

Registered

2015-11-23

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retreatment gynecological cancer Ovarian cancer Peritoneal cancer Hypersensitivity reaction Carboplatin Retreatment Gynecological cancer Ovarian cancer Peritoneal cancer Hypersensitivity reaction Anaphylaxis Adverse drug reactions

Interventions

1. The patients will be administered the premedication 30 minutes before start the chemotherapy (Carboplatin&#45

included regimen). (Premedication include: &#45

Lorazepam (0.5 mg) 1 tablets orally &#45

Dexamethasone 20 mg + ondansetron 8 mg + 5%DW 100 mL iv drip 50 drops/minute &#45

Ranitidine 50 mg iv slowly push (over 2 minutes) &#45

Chlorpheniramine 1 ampule iv slowly push) 2. The patients will be administered the carboplatin (AUC=5) iv in 1 hour. 3. The patients will be record the vital sign and any hypersensitivity symptoms by

the nurse will record and report to the doctor for management (NCCN guideline).,1. The patients will be administered the premedication 30 minutes before start the chemotherapy (Carboplatin&#45

Chlorpheniramine 1 ampule iv slowly push) 2. The patients will be administered the carboplatin (AUC=5) iv in 2 hours. 3. The patients will be record the vital sign and any hypersensitivity symptoms by

the nurse will record and report to the doctor for management (NCCN guideline).

Placebo Comparator Other,Experimental Other

1 hour infusion of Carboplatin (Controlled group),2 hours infusion of Carboplatin (Study group)

Eligibility

Sex/Gender

Female

Age

25 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Gynecological cancer patients age between 25-80 years old 2. Historically treated by carboplatin-included regimen at least 6 cycles 3. Need for retreatment by carboplatin-included regimen again

Exclusion criteria

Exclusion criteria: 1. Historically occured of hypersensitivity reaction to carboplatin 2. No history of treatment by carboplatin

Design outcomes

Primary

Measure	Time frame
Hypersensitivity occuring rate At the day of chemotherapy was administered The data about hypersensitivity at the day of chemotherapy was administered will be recorded by the	—

Secondary

Measure	Time frame
none none none	—

Countries

Thailand

Contacts

Public ContactWeerawich Pornwattnakrilert

Obstetrics and Gynecologic Department, Faculty of Medicine, Chiang Mai University

weerawich.medic32@gmail.com+66 852401314

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026